TO THE EDITOR: In 2015, a task force of oncologists coordinated by ASCO developed a complex consensus document that examined the main determinants of effectiveness for current anticancer treatments along with data on treatment costs. 1, 2 In particular, data on effectiveness and cost were combined to produce a series of information that patients can use-together with oncologists-to select their treatment from available options. In the same year, another project with similar characteristics was carried out by the European Society for Medical Oncology (ESMO). The ESMO report 3 was aimed at determining the magnitude of clinical benefit from anticancer therapies by using a standardized approach. This report showed an important difference because costs were not included in the analysis. Overall, the degree of technicality of both these documents was kept to a minimum, and one important reason for this choice is that the scores-and especially the ASCO score-were designed to also be used by patients.
The ASCO task force document and the ESMO report share an important characteristic as both generate a score that quantifies the incremental clinical benefit that is associated with a new treatment compared with the standard of care. These scores are denoted as net health benefit score in the ASCO tool and magnitude of clinical benefit score in the ESMO tool.
Before the availability of these two tools, determining the incremental benefit in the health care decision process had been a task typically given to health technology assessment (HTA) evaluations. 4, 5 In fact, for many decades, gain in survival or in quality-adjusted survival has been the mainstay of the decision process of HTA, and there is worldwide experience surrounding this point. 4, 6 In the current context, where these two new tools have been made available, an essential question is to determine whether the scores generated by the two methods correlate with the values of survival gain. The analyses described herein, which are aimed at this objective, have been focused on the ESMO method-and not the ASCO method-mainly because the documentation needed to test a series of real examples was available for the former method and not for the latter.
Hence, to test the correlation between survival gains and ESMO scores, we analyzed the data reported in Tables 3 to 12 in the study by Cherny et al. 3 Information on overall survival (OS) and progressionfree survival (PFS) was evaluated in two separate analyses. All statistical calculations were carried out by using SPSS for Windows version 22 (SPSS, Chicago, IL).
The results of our analyses are summarized in These results raise some concern mainly because ESMO scores seem to reflect a decision criterion that is different from that which has been used for more than 20 years in all HTA analyses. Regarding the ASCO task force method, the original paper that describes this new evaluation approach 1,2 did not include a detailed description of a series of examples, and so we could not carry out statistical analysis to test whether scores, that is, the net health benefit score, correlated with gains; however, such an analysis could easily be performed by the task force group.
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